Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression

Prostate Cancer and Prostatic Diseases

Volumn 9, Issue 3, 2006, Pages 279-283

  Augustin, H ^a   Freibauer, C ^b   Bayer, L ^c   Lunglmayr, G ^c   Tschurlovich, F ^d   Kuber, W ^d   Pummer, K ^a  

^a UNIVERSITY HOSPITAL GRAZ   (Austria)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^c Mistelbach General Hospital   (Austria)

^d General Hospital of Oberwart   (Austria)

Author keywords

Intermitted androgen suppression; Oncogenes; Proliferation markers; Prostate cancer

Indexed keywords

BICALUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; KI 67 ANTIGEN; MOLECULAR MARKER; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P53; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; ANTIGEN DETECTION; APOPTOSIS; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; REGRESSION ANALYSIS; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CARCINOMA; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GOSERELIN; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NITRILES; PROGNOSIS; PROSTATIC NEOPLASMS; TESTOSTERONE; TOSYL COMPOUNDS; TUMOR MARKERS, BIOLOGICAL; WITHHOLDING TREATMENT;

EID: 33748279103     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500883     Document Type: Article

References (28)

1. Huggins C, Hodges C. Studies of prostatic cancer: I. Effect of castration, estrogen and androgen injections on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
2. Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004; 64: 1182-1186.
3. Fossa SD, Woehre H, Kurth KH, Hetherington J, Bakke H, Rustad DA et al. Influence of urological morbidity on quality of life in patients with prostate cancer. Eur Urol 1997; 31(Suppl 3): 3-8.
4. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 1995; 45: 839-844.
5. De La Taille A, Zerbib M, Conquy S, Amsellem-Ouazana D, Thiounn N, Flam TA et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int 2003; 91: 18-22.
6. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumours. Apoptosis and serum prostate-specific antigen. Cancer 1993; 71: 2782-2790.
7. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 1996; 58: 139-146.
8. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
9. Mostofi FK. Grading of prostatic carcinoma. Cancer Chemother Rep 1975; 59: 111-117.
10. Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: Preliminary report of a prospective multicenter study. Urology 2004; 64: 341-345.
11. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res 1997; 57: 1584-1589.
12. Crook JM, Szumacher E, Malone S, Huan S, Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology 1999; 53: 530-534.
13. Grossfeld GD, Chaudhary UB, Reese DM, Carroll PR, Small EJ. Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 2001; 58: 240-245.
14. Albrecht W, Collette L, Fava C, Kariakine OB, Whelan P, Studer UE et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: An EORTC feasibility study. Eur Urol 2003; 44: 505-511.
15. Prapotnich D, Fizazi K, Escudier B, Mombet A, Cathala N, Vallancien G. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003; 43: 233-239.
16. Koivisto P, Visakorpi T, Rantala I, Isola J. Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. J Pathol 1997; 183: 51-56.
17. Paterson RF, Gleave ME, Jones EC, Zubovits JT, Goldenberg SL, Sullivan LD. Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormonal therapy. Mol Urol 1999; 3: 277-286.
18. Matsushima H, Goto T, Hosaka Y, Kitamura T, Kawabe K. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer 1999; 85: 1822-1827.
19. Miyata Y, Kanda S, Sakai H, Hakariya T, Kanetake H. Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment. Urology 2005; 65: 1238-1243.
20. Lu Q-L, Abel P, Foster CS, Lalani E-M. Bcl-2: Role in epithelial differentiation and oncogenesis. Hum Pathol 1996; 27: 102-110.
21. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993; 143: 390-400.
22. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of Bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55: 4438-4445.
23. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-1093.
24. Grossfeld GD, Olumi AF, Connolly JA, Chew K, Gibney J, Bhargava V et al. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in KI-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol 1998; 159: 1437-1443.
25. Stapleton AM, Zbell P, Kattan MW, Yang G, Wheeler TM, Scardino PT et al. Assessment of the biological markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 1998; 82: 168-175.
26. Lewis JS, Vollmer RT, Humphrey PA. Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population. Am J Clin Pathol 2002; 118: 442-450.
27. Klotz L, Correia A, Zhang W. The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer. Prostate Cancer Prostatic Dis 2005; 8: 179-183.
28. Pether M, Goldenberg SL. Intermittent androgen suppression. BJU Int 2004; 93: 258-261.